Everolimus Plus Endocrine Therapy for Postmenopausal Women With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer A Clinical Trial


Royce M., BACHELOT T., VILLANUEVA C., Ozguroglu M. , AZEVEDO S. J. , CRUZ F. M. , ...More

JAMA ONCOLOGY, vol.4, no.7, pp.977-984, 2018 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 4 Issue: 7
  • Publication Date: 2018
  • Doi Number: 10.1001/jamaoncol.2018.0060
  • Title of Journal : JAMA ONCOLOGY
  • Page Numbers: pp.977-984

Abstract

IMPORTANCE Cotargeting the mammalian target of rapamycin pathway and estrogen receptor may prevent or delay endocrine resistance in patients receiving first-line treatment for advanced breast cancer.